Controlled Substances Act, FDA Approval

FDA Issues New Draft Guidance on Clinical Testing of Psychedelic Drugs

Manatt, Phelps & Phillips, LLP on 6/29/2023

On June 23, 2023, FDA issued a first-of-its-kind draft guidance for sponsors of studies of psychedelic drugs. The guidance arrived just as the Psychedelic Science 2023 conference in Denver was wrapping up. Touted as the...more

Global Patent Prosecution - June 2019: Hemp Legalization and the International CBD Boom

Sterne, Kessler, Goldstein & Fox P.L.L.C. on 6/17/2019

Products containing cannabidiol (“CBD”), a compound derived from cannabis plants, are part of a growing market segment that is on a fast-track to becoming global within the next five years. CBD-containing products, from gummy...more

Despite Lawful Use in Commerce, Hemp and CBD Trademarks May Still Face Rejection

Harris Beach PLLC on 2/19/2019

In a previous Legal Alert, we covered the removal of one impediment to federal trademark registration for hemp/CBD products: namely, that hemp/CBD products will no longer be outlawed by the Controlled Substances Act and will...more

Important Legislative and Regulatory Changes Impacting the Commercialization of Cannabis, Hemp, and CBD

Wilson Sonsini Goodrich & Rosati on 2/7/2019

A number of important changes have occurred in the cannabis, hemp, and cannabidiol (CBD) spaces. This alert presents a snapshot of significant developments and selected future predictions....more

The Path to Greenlighting CBD

Burns & Levinson LLP on 10/1/2018

Last week, the industry was energized by the Drug Enforcement Administration’s order placing certain drugs containing cannabidiol, or CBD, in Schedule V of the Controlled Substances Act. This marks the first time in history...more

Hemp News Highlights

Ward and Smith, P.A. on 7/2/2018

We've previously published articles about industrial hemp and the excitement and curiosity it continues to garner as a cash crop in North Carolina. That trend continues to develop, and recently there have been several...more